Less-invasive and highly effective method for preventing methicillin-resistant Staphylococcus aureus graft infection by local sustained release of vancomycin

The Journal of Thoracic and Cardiovascular Surgery
Hisashi SakaguchiMasashi Komeda

Abstract

Methicillin-resistant Staphylococcus aureus graft infection is one of the most serious complications of vascular surgery. Vancomycin is a potent antibiotic against methicillin-resistant S. aureus; however, systemic administration of vancomycin is not very effective against methicillin-resistant S. aureus graft infection. Therefore, we investigated whether a local sustained release of vancomycin prevents methicillin-resistant S. aureus graft infection. We have developed a poly-L-lactide-co-caprolactone sheet that enabled sustained release of vancomycin for 2 weeks. An expanded polytetrafluoroethylene vascular graft patch (1.5 mm2) was sutured at the anterior wall of the incised murine abdominal aorta. Methicillin-resistant S. aureus (1.0 x 10(3) colony-forming units) was inoculated onto the graft surface. Thereafter, the graft was treated as follows (n = 6 each): no treatment (control group), local injection of an aqueous solution of vancomycin (vancomycin solution group) and local implantation of poly-L-lactide-co-caprolactone containing vancomycin (vancomycin-PLCA group). After 7 days, the graft and blood were sampled and cultured. The methicillin-resistant S. aureus counts in the grafts of the vancomycin-PLCA group were signi...Continue Reading

References

Sep 19, 1997·Journal of Biomedical Materials Research·K FujimotoY Nimura
Feb 17, 1998·Cardiovascular Surgery : Official Journal of the International Society for Cardiovascular Surgery·L JonesJ J Earnshaw
Sep 16, 1999·American Journal of Surgery·R M YoungJ W Hallett
Nov 4, 2000·The Journal of Antimicrobial Chemotherapy·A GiacomettiV Saba
Aug 17, 2001·European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery·A NasimN J London
Oct 9, 2003·European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery·T Hernández-RichterM K Angele
Oct 7, 2004·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·G GiavaresiR Giardino
May 27, 2006·European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery·A YasimY Ergun

❮ Previous
Next ❯

Citations

Apr 3, 2010·Interactive Cardiovascular and Thoracic Surgery·Manabu MorishimaRyuzo Sakata
Mar 19, 2014·Journal of Oral and Maxillofacial Surgery : Official Journal of the American Association of Oral and Maxillofacial Surgeons·Robert A WaeissMarco C Bottino
Jun 12, 2010·The Journal of Surgical Research·Karem C HarthHorst A von Recum
Mar 5, 2009·The Journal of Thoracic and Cardiovascular Surgery·Akira MaruiMasashi Komeda
Sep 23, 2008·The Annals of Thoracic Surgery·Shinichi SatoKoichi Tabayashi
Feb 20, 2009·Current Opinion in Otolaryngology & Head and Neck Surgery

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.